Assessment of verapamil in the treatment of angina pectoris. 1975

F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin

A brief review is given of the pharmacological data of verapamil, which chemically shows a certain similarity to papaverine. The effect of the drug (80 mg) 3 times daily, on angina pectoris, as compared with placebo, was evaluated in a double-blind cross-over therapeutic trial with 4-wk periods in 47 patients. The incidence of attacks and the nitroglycerine consumption decreased in the second fortnight of the verapamil period by approximately 25% compared with the placebo period. An ergometer test showed a prolongation of the exerice time of 20%. The mean blood pressure and the heart rate fell under verapamil treatment if the patients had values which were relatively high in the placebo period. The increase in heart rate during exercise from two different resting levels showed a tendency to become more pronounced under treatment with verapamil than under placebo. The length of the P-Q intervals were not affected by verapamil. The mechanism of action in angina pectoris is discussed, but it is concluded that it is still not possible to explain it. Twelve Danish medical departments took part in the trial.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010208 Papaverine An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. Cerespan,Papaverine Hydrochloride,Pavabid,Pavatym,Hydrochloride, Papaverine
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005080 Exercise Test Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. Arm Ergometry Test,Bicycle Ergometry Test,Cardiopulmonary Exercise Testing,Exercise Testing,Step Test,Stress Test,Treadmill Test,Cardiopulmonary Exercise Test,EuroFit Tests,Eurofit Test Battery,European Fitness Testing Battery,Fitness Testing,Physical Fitness Testing,Arm Ergometry Tests,Bicycle Ergometry Tests,Cardiopulmonary Exercise Tests,Ergometry Test, Arm,Ergometry Test, Bicycle,Ergometry Tests, Arm,Ergometry Tests, Bicycle,EuroFit Test,Eurofit Test Batteries,Exercise Test, Cardiopulmonary,Exercise Testing, Cardiopulmonary,Exercise Tests,Exercise Tests, Cardiopulmonary,Fitness Testing, Physical,Fitness Testings,Step Tests,Stress Tests,Test Battery, Eurofit,Test, Arm Ergometry,Test, Bicycle Ergometry,Test, Cardiopulmonary Exercise,Test, EuroFit,Test, Exercise,Test, Step,Test, Stress,Test, Treadmill,Testing, Cardiopulmonary Exercise,Testing, Exercise,Testing, Fitness,Testing, Physical Fitness,Tests, Arm Ergometry,Tests, Bicycle Ergometry,Tests, Cardiopulmonary Exercise,Tests, EuroFit,Tests, Exercise,Tests, Step,Tests, Stress,Tests, Treadmill,Treadmill Tests

Related Publications

F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
September 1970, Arzneimittel-Forschung,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
January 1986, British journal of clinical pharmacology,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
June 1985, British journal of clinical practice. Supplement,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
September 1970, Bruxelles medical,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
July 1980, The Medical journal of Australia,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
January 1982, Clinical and experimental pharmacology & physiology. Supplement,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
September 1968, Journal of the Indian Medical Association,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
January 1982, Ugeskrift for laeger,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
June 1982, The Medical letter on drugs and therapeutics,
F Andreasen, and E Boye, and E Christoffersen, and P Dalsgaard, and E Henneberg, and A Kallenbach, and S Ladefoged, and K Lillquist, and E Mikkelsen, and E Norder0, and J Olsen, and J K Pedersen, and V Pedersen, and G B Petersen, and J Schroll, and H Schultz, and J Seidelin
October 1990, Journal of clinical pharmacology,
Copied contents to your clipboard!